Concert Pharmaceuticals Inc. (NASDAQ:CNCE)’s share price was up 5.9% on Tuesday . The stock traded as high as $10.24 and last traded at $10.23, with a volume of 285,371 shares changing hands. The stock had previously closed at $9.66.

Several equities analysts recently weighed in on CNCE shares. Brean Capital reissued a “buy” rating and issued a $25.00 target price on shares of Concert Pharmaceuticals in a research note on Friday, May 6th. Zacks Investment Research raised shares of Concert Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, May 17th. Finally, Stifel Nicolaus assumed coverage on shares of Concert Pharmaceuticals in a research report on Friday, July 1st. They set a “buy” rating and a $23.00 price objective for the company. Two investment analysts have rated the stock with a sell rating and six have assigned a buy rating to the stock. Concert Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $26.43.

The stock’s market capitalization is $216.05 million. The firm has a 50 day moving average price of $11.27 and a 200-day moving average price of $12.44.

Concert Pharmaceuticals (NASDAQ:CNCE) last issued its earnings results on Tuesday, August 9th. The company reported ($0.60) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.03. On average, analysts forecast that Concert Pharmaceuticals Inc. will post ($2.51) EPS for the current fiscal year.

Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others segment. It has clinical candidates under development, including AVP-786, CTP-656, CTP-730 and JZP-386.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.